Antibodies Journal

evitria’s HTP Antibody Production Service delivers purified, analytics-confirmed material within a 4-week cycle from sequence approval. Learn what factors influence turnaround time and how to plan your screening campaign effectively.

Identifying a high-affinity binder is only the first hurdle in antibody discovery. Developability-by-Design integrates five key biophysical readouts into the selection process to ensure only manufacturable candidates advance.

Top-tier HTP screening leads frequently fail to translate to manufacturing due to host system incompatibilities and production artefacts. This article examines the root causes and how to close the translation gap.

High-Throughput Screening bridges antibody production and data generation, transforming large panels of expressed proteins into actionable biological insights. Understanding this workflow is essential for designing a productive discovery campaign.

High-Throughput Antibody Expression accelerates early-stage discovery by translating digital sequence libraries into physical proteins at unprecedented speed. Discover how HTP production compresses the path from sequence to validated lead.

High-throughput antibody expression exposes technical liabilities that remain invisible until they cause failure at scale. This article identifies the five most common problems and how to proactively avoid them.

Reliable lead comparability in an HTP screening campaign depends on high-fidelity production and a consistent host system. This guide outlines how to structure your campaign to generate decision-grade data.

The host system used during primary screening determines whether lead candidates are genuinely ready for development. CHO-based material ensures data generated at the screening stage translates directly to manufacturing.

Choosing HEK293 cells based on lower upfront cost introduces hidden downstream risks that can cost millions in failed preclinical development. Understanding the true economics of host system selection is critical.

Batch effects are systematic, non-biological sources of variation that distort HTP screening results. Identifying their root causes and applying targeted reduction strategies is essential for reliable lead selection.